The 36-month beta value for TARS is also noteworthy at 1.06. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TARS is 29.00M, and at present, short sellers hold a 27.07% of that float. The average trading volume of TARS on April 12, 2024 was 792.11K shares.
TARS) stock’s latest price update
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) has experienced a rise in its stock price by 6.72 compared to its previous closing price of 35.88. However, the company has seen a gain of 9.59% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-08 that The average of price targets set by Wall Street analysts indicates a potential upside of 47.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TARS’s Market Performance
Tarsus Pharmaceuticals Inc (TARS) has seen a 9.59% rise in stock performance for the week, with a 25.09% gain in the past month and a 81.56% surge in the past quarter. The volatility ratio for the week is 4.75%, and the volatility levels for the past 30 days are at 5.78% for TARS.. The simple moving average for the past 20 days is 12.84% for TARS’s stock, with a 76.75% simple moving average for the past 200 days.
Analysts’ Opinion of TARS
Many brokerage firms have already submitted their reports for TARS stocks, with Goldman repeating the rating for TARS by listing it as a “Neutral.” The predicted price for TARS in the upcoming period, according to Goldman is $19 based on the research report published on November 20, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see TARS reach a price target of $44. The rating they have provided for TARS stocks is “Outperform” according to the report published on July 18th, 2023.
TARS Trading at 16.54% from the 50-Day Moving Average
After a stumble in the market that brought TARS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.22% of loss for the given period.
Volatility was left at 5.78%, however, over the last 30 days, the volatility rate increased by 4.75%, as shares surge +22.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.29% upper at present.
During the last 5 trading sessions, TARS rose by +9.59%, which changed the moving average for the period of 200-days by +123.27% in comparison to the 20-day moving average, which settled at $34.28. In addition, Tarsus Pharmaceuticals Inc saw 89.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TARS starting from Azamian Bobak R., who sale 10,415 shares at the price of $30.60 back on Mar 18 ’24. After this action, Azamian Bobak R. now owns 26,456 shares of Tarsus Pharmaceuticals Inc, valued at $318,699 using the latest closing price.
Neervannan Seshadri, the Chief Operating Officer of Tarsus Pharmaceuticals Inc, sale 4,879 shares at $30.60 during a trade that took place back on Mar 18 ’24, which means that Neervannan Seshadri is holding 64,767 shares at $149,297 based on the most recent closing price.
Stock Fundamentals for TARS
Current profitability levels for the company are sitting at:
- -4.37 for the present operating margin
- 0.93 for the gross margin
The net margin for Tarsus Pharmaceuticals Inc stands at -4.11. The total capital return value is set at -0.62. Equity return is now at value -69.71, with -55.01 for asset returns.
Based on Tarsus Pharmaceuticals Inc (TARS), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.89. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is -87.83.
Currently, EBITDA for the company is -142.28 million with net debt to EBITDA at 1.4. When we switch over and look at the enterprise to sales, we see a ratio of 37.97. The receivables turnover for the company is 1.85for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.93.
Conclusion
In summary, Tarsus Pharmaceuticals Inc (TARS) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
